Open an account

Hologic

HOLX · NASDAQ

Price unavailable right now.

No price history for this range.

About HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focus on women’s health and well-being through early detection and treatment. The company is headquartered in Marlborough, Massachusetts and currently employs 7,070 full-time employees. The firm is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

Employees
7,070
Headquarters
Marlborough, Massachusetts
Listed
Mar 1, 1990
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
hologic.com

HOLX key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 10 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 16 analystsAvg $76.66
Low
$70.70
High
$81.90

HOLX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 2.1% on average.

  1. Q2 FY24: reported $1.03 per share against an estimate of $0.9971
  2. Q3 FY24: reported $1.06 per share against an estimate of $1.04
  3. Q4 FY24: reported $1.01 per share against an estimate of $1.03
  4. Q1 FY25: reported $1.03 per share against an estimate of $1.04
  5. Q2 FY25: reported $1.03 per share against an estimate of $1.04
  6. Q4 FY25: reported $1.04 per share against an estimate of $1.11
  7. Q3 FY25: reported $1.13 per share against an estimate of $1.12
  8. Q1 FY26: reported $1.04 per share against an estimate of $1.11

HOLX news

  • Press releaseBusiness Wire

    Blackstone and TPG Complete Acquisition of Hologic

  • Press releasePRNewswire

    Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

  • Press releaseBusiness Wire

    Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction

  • Press releaseBusiness Wire

    1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates

  • Press releaseBusiness Wire

    Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

  • Press releaseBusiness Wire

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

  • Examining the Future: Hologic's Earnings Outlook

  • Press releasePRNewswire

    Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

Similar companies

Companies in the same industry as Hologic

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.